Latest News and Press Releases
Want to stay updated on the latest news?
-
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
-
IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
-
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
-
IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences
-
IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025
-
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
-
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
-
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
-
Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next generation γδ TCE targeting CD19,...
-
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that...